{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:44:59Z","timestamp":1790815499571,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,2,28]],"date-time":"2012-02-28T00:00:00Z","timestamp":1330387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2012,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the interleukin\u20101 inhibitor rilonacept (Interleukin\u20101 Trap) for prevention of gout flares occurring in the first few months following initiation of urate\u2010lowering therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this double\u2010blind study, adult patients with hyperuricemia and gout were randomized to receive rilonacept administered subcutaneously once per week (loading dose 320 mg followed by 160 mg weekly) or placebo, and started on allopurinol (300 mg\/day, titrated to serum urate &lt;6 mg\/dl). At study visits, physical and laboratory assessments were performed and information on any adverse events was ascertained.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Baseline characteristics were similar between the rilonacept and placebo groups (n = 41 and n = 42, respectively). The mean number of gout flares per patient through week 12 (primary efficacy end point) was markedly lower in the rilonacept group than in the placebo group (0.15 [6 flares] versus 0.79 [33 flares]; <jats:italic>P<\/jats:italic> = 0.0011). Fewer flares were observed with rilonacept as early as 4 weeks after initiation of treatment (<jats:italic>P<\/jats:italic> = 0.007). The proportion of patients experiencing a flare during the 12 weeks was lower in the rilonacept group than in the placebo group (14.6% versus 45.2%; <jats:italic>P<\/jats:italic> = 0.0037). No rebound in the flare rate was observed for 6 weeks after discontinuation of rilonacept or placebo at week 16. Adverse events were similar between groups, and no deaths or serious infectious adverse events were reported; the most common adverse events were infections (14.6% and 26.2% of rilonacept\u2010 and placebo\u2010treated patients, respectively) and musculoskeletal disorders (14.6% and 21.4%, respectively). A higher percentage of rilonacept\u2010treated patients (98%) compared with placebo\u2010treated patients (79%) completed the primary 12\u2010week evaluation period (<jats:italic>P<\/jats:italic> = 0.015).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The current findings indicate that rilonacept significantly reduces the frequency of gout flares during the initial period of treatment with urate\u2010lowering therapy, with a favorable safety profile.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.33412","type":"journal-article","created":{"date-parts":[[2012,1,5]],"date-time":"2012-01-05T11:58:30Z","timestamp":1325764710000},"page":"876-884","source":"Crossref","is-referenced-by-count":91,"title":["Rilonacept (Interleukin\u20101 Trap) in the prevention of acute gout flares during initiation of urate\u2010lowering therapy: Results of a phase II randomized, double\u2010blind, placebo\u2010controlled trial"],"prefix":"10.1002","volume":"64","author":[{"suffix":"Jr.","given":"H. Ralph","family":"Schumacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Sundy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Terkeltaub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard R.","family":"Knapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Mellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George D.","family":"Yancopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhwen","family":"Soo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirletta","family":"King\u2010Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen R.","family":"Radin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"0619 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,2,28]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20438"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.75.Suppl_5.S22"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21634"},{"key":"e_1_2_7_5_2","first-page":"1575","article-title":"Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims","volume":"31","author":"Riedel AA","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.4065\/81.7.925"},{"key":"e_1_2_7_7_2","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad GC","year":"2004","journal-title":"J Rheumatol"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200724010-00002"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature04516"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.109355"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.073759"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar2143"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108936"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23687"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm811"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780200320"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90743-5"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.144063"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050373"},{"key":"e_1_2_7_20_2","unstructured":"Takeda Pharmaceuticals North America Inc.Febuxostat 40 mg and 80 mg NDA no. 21\u2010856 indication: treatment of hyperuricemia in patients with gout. Briefing document for Advisory Committee Division of Anesthesia Analgesia and Rheumatology Products FDA Advisory Committee Meeting November 24 2008."},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0336"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.10.002"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464210-00003"},{"key":"e_1_2_7_24_2","first-page":"1381","article-title":"Outcome evaluations in gout","volume":"34","author":"Schumacher HR","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20405"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.rhu.0000209882.50228.9f"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.060368"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.33412","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.33412","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.33412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T23:22:48Z","timestamp":1696980168000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.33412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,28]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["10.1002\/art.33412"],"URL":"https:\/\/doi.org\/10.1002\/art.33412","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,28]]}}}